Pacer Advisors, Inc. Fate Therapeutics Inc Transaction History

Pacer Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$3.26 - $7.08 $6,415 - $13,933	-1,968 Reduced 57.98%	1,426 $4,000
Q1 2024 May 10, 2024	BUY	$3.54 - $8.35 $12,014 - $28,339	3,394 New	3,394 $24,000
Q2 2021 Jul 21, 2021	SELL	$67.25 - $92.52 $55,279 - $76,051	-822 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$72.16 - $117.4 $41,564 - $67,622	-576 Reduced 41.2%	822 $68,000
Q4 2020 Jan 20, 2021	SELL	$38.09 - $100.95 $76,941 - $203,919	-2,020 Reduced 59.1%	1,398 $127,000
Q3 2020 Oct 19, 2020	BUY	$30.41 - $40.5 $103,941 - $138,429	3,418 New	3,418 $137,000
Q4 2018 Feb 13, 2019	SELL	$11.48 - $16.98 $50,259 - $74,338	-4,378 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $38,307 - $71,317	4,378 New	4,378 $71,000

178

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $129M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.